Guggenheim Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating restated by Guggenheim in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $12.00 price target on the stock. Guggenheim’s price objective indicates a potential upside of 454.27% from the stock’s current price.

Several other research analysts have also recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday. Leerink Partners upgraded shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the company from $4.00 to $6.00 in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a report on Tuesday. Finally, Jefferies Financial Group boosted their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $11.63.

Compass Therapeutics Stock Performance

Compass Therapeutics stock traded down $0.08 during midday trading on Wednesday, hitting $2.17. 1,945,153 shares of the company’s stock were exchanged, compared to its average volume of 784,349. The stock has a market cap of $299.38 million, a price-to-earnings ratio of -5.88 and a beta of 1.19. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08. The firm’s 50 day simple moving average is $2.83 and its 200 day simple moving average is $2.11.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, equities research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Enavate Sciences GP LLC acquired a new position in shares of Compass Therapeutics in the fourth quarter worth about $11,293,000. Tang Capital Management LLC grew its holdings in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC boosted its holdings in Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after acquiring an additional 2,926,002 shares during the period. SG Americas Securities LLC grew its stake in shares of Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Compass Therapeutics by 512.5% during the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock valued at $395,000 after acquiring an additional 227,864 shares during the period. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.